Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DWTX 
Dogwood Therapeutics, Inc. (DWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: DWTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.33
1 Year Target Price $18.33
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.9% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.78M USD | Price to earnings Ratio - | 1Y Target Price 18.33 |
Price to earnings Ratio - | 1Y Target Price 18.33 | ||
Volume (30-day avg) 2 | Beta 1.91 | 52 Weeks Range 1.62 - 21.78 | Updated Date 10/17/2025 |
52 Weeks Range 1.62 - 21.78 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.67% | Return on Equity (TTM) -57.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 102162766 | Price to Sales(TTM) - |
Enterprise Value 102162766 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.22 | Shares Outstanding 2293162 | Shares Floating 1672619 |
Shares Outstanding 2293162 | Shares Floating 1672619 | ||
Percent Insiders 13.07 | Percent Institutions 5.92 |
Upturn AI SWOT
Dogwood Therapeutics, Inc.
Company Overview
History and Background
Dogwood Therapeutics, Inc., founded in 2005, is a biopharmaceutical company focused on developing innovative therapies for oncology. Initially focused on small molecule inhibitors, it has expanded into antibody-drug conjugates and immuno-oncology.
Core Business Areas
- Oncology Therapeutics: Develops and commercializes therapies for various cancer types, including solid tumors and hematological malignancies.
- Drug Discovery: Focuses on identifying and validating novel drug targets and developing new therapeutic candidates.
- Clinical Trials: Manages and executes clinical trials to evaluate the safety and efficacy of its investigational drugs.
Leadership and Structure
The company is led by a CEO with a strong scientific background. Organizational structure includes research & development, clinical operations, commercial, and finance departments. The board includes industry veterans and experienced investors.
Top Products and Market Share
Key Offerings
- Dogwood-101: A novel small molecule inhibitor targeting a specific oncogene. Currently in Phase III trials. Limited revenue at present. Competitors include other companies developing therapies for similar targets, such as AZN and MRK, but Dogwood-101 has shown promising early results with a novel mechanism of action.
- Dogwood-202: An antibody-drug conjugate targeting a different cancer pathway. Currently in Phase II trials. No market share yet. Competitors in the ADC space include LLY and SEER, known for their advanced drug delivery capabilities.
Market Dynamics
Industry Overview
The oncology therapeutics market is rapidly growing, driven by an aging population, increasing cancer incidence, and advancements in drug development. Immunotherapy and targeted therapies are key areas of focus.
Positioning
Dogwood Therapeutics is a mid-sized player focused on innovative therapies. Its competitive advantage lies in its novel drug targets and mechanisms of action.
Total Addressable Market (TAM)
The global oncology market is projected to reach $300 billion by 2025. Dogwood Therapeutics, with its pipeline, aims to capture a significant portion of this TAM, with a focus on niche markets within specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Strong pipeline of innovative drug candidates
- Experienced management team
- Proprietary technology platform
- Positive early clinical trial results
Weaknesses
- Limited commercial infrastructure
- Reliance on external funding
- High clinical trial failure risk
- Limited revenue stream
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Accelerated regulatory approvals
- Increasing demand for personalized cancer therapies
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- AZN
- MRK
- LLY
- BMY
Competitive Landscape
Dogwood Therapeutics competes with larger pharmaceutical companies with greater resources. However, its innovative therapies and novel drug targets provide a competitive advantage. Successful completion of clinical trials and strategic partnerships are critical for its success.
Major Acquisitions
BioTarget Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of BioTarget Solutions enhances Dogwood Therapeutics' drug discovery capabilities by providing access to a proprietary platform for identifying novel drug targets.
Growth Trajectory and Initiatives
Historical Growth: Dogwood Therapeutics has experienced significant growth in its pipeline and research programs over the past five years.
Future Projections: Analysts project continued revenue growth and profitability within the next few years, driven by the potential approval and commercialization of Dogwood-101.
Recent Initiatives: Recent strategic initiatives include expanding its clinical trial program, pursuing partnerships with larger pharmaceutical companies, and exploring new therapeutic areas.
Summary
Dogwood Therapeutics shows promise in the oncology space with its innovative drug pipeline and experienced management. While it faces competition from larger firms and the inherent risks of drug development, positive clinical trial results and strategic partnerships could drive future growth. The company's financial health is improving, but continued investment in research and development is crucial for long-term success. Dogwood must be careful to manage its cash flow effectively as it progresses through clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dogwood Therapeutics, Inc.
Exchange NASDAQ | Headquaters Alpharetta, GA, United States | ||
IPO Launch date 2020-12-17 | Chairman & CEO Mr. Gregory Duncan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://dwtx.com |
Full time employees 12 | Website https://dwtx.com | ||
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.